PTC Therapeutics climbs after guidance hike

2026-05-08 13:00:34 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease - Slideshow PTC outlines 2026 product revenue guidance of $750M-$850M driven by Sephience launch momentum PTC Therapeutics GAAP EPS of -$0.03 beats by $0.44, revenue of $272.55M beats by $47.2M Read the full article on Seeking Alpha For further details see: PTC Therapeutics climbs after guidance hike